We identified non-canonical NFκB activation of GLI1 in these cells, indicating crosstalk between GLI1 signaling and NFκB pathways in claudin-low and EMT breast cancer cells and suggesting a therapeutic route for claudin-low breast cancer. This evidence concerns the gene NFKB1 and breast carcinoma.